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Summary
Background: The Charnley stem provides good outcome for 10 years, but several studies ﬁnd
deteriorating results thereafter. However, study populations, techniques and data analysis vary
widely. We have studied 240 Charnley stems in a homogeneous group of patients providing
clinical, radiological and survival data after 11—14 years.
Hypothesis: The clinical and radiological outcome of the Charnley stem is not as good than
previously thought.
Patients and methods: Five surgeons implanted 240 femoral stems in a community hospital in
Norway using antibiotic impregnated cement and third generation cementing techniques. The
Charnley stems were implanted with a Charnley cup in 120 cases and an uncemented hemi-
spherical cup (DuralocTM) in 120 cases. The mean age of the patients was 65.5 years and the
mean Body Mass Index (BMI) was 26.8. All patients received low molecular weight heparin and
antibiotic prophylaxis. Patients were assessed after 10 years by means of Harris Hip Score (HHS)
and radiographic evaluation. Implant survival studies were performed after 11—14 years.
Results: One hundred and ﬁfty-eight patients were available for clinical and radiographic eval-
uation after 10 years. HHS improved from 48.4 (95% CI: 46.6—50,2) preoperatively to 87.9 (95%
CI: 86.6—89.3) after 6months and 87.6 (95% CI: 85.3—89.8) at 10 years. Thirty-one stems had
been revised, the reasons for revision were loosening (21), infection (ﬁve), instability (four)
and late perisprosthetic fracture (one). Forty-one stems had one or more signs of loosening.
Stem survival was 83.6% using any revisions as end point, and mean estimated stem survival
was 12.7 years (12.2—13.3 years).
Discussion: Other studies report survival at mid-term from 83—96%. Our results are in the
low-end. Even though our rate of infection was high (2%), the main cause of the poor results
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the evidence that the Charnley stem should not be used hip arthroplasty unless patient life
expectancy is less than 10 years.
Level of evidence: Level 2 prospective clinical study.
© 2010 Published by Elsevier Masson SAS.
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Table 1 Charnley classiﬁcation including modiﬁcation of
group B.
A Single joint arthropathy and no
signiﬁcant medical comorbidity
112
B One other joint in need of an
arthroplasty, or an unsuccessful or
failing arthroplasty in another joint
118a
B1 Contralateral hip in need of
arthroplasty, but untreated
64
B2 Contralateral hip has been
successfully treated with an
arthroplasty
54
C Multiple joints in need of
arthroplasty, multiple failing
10
Duraloc 1200TM cup (DePuy, Leeds, UK) in 120 cases. We used
randomization by means of closed envelope for allocation of
acetabular components.
We used dalteparin (Fragmin®), a low molecular weight
heparin, 5000 IE subcutaneously for prophylaxis against
thromboembolic events on the night before surgery, 4—8 h
Table 2 Diagnosis, age and type of implants used in the
study.
Diagnosis
Osteoarthritis 187
Congenital hip dysplasia 42
Post-traumatic arthritis 6
Rheumatoid arthritis 4
Avascular necrosis 1
Sex
Male 64
Female 176
Types of implants
Flanged 40 115
Roundback 40 30
Long neck 24
Extra heavy long neck 13ntroduction
otal hip arthroplasty (THA) is an effective treatment for
nd-stage degenerative disease of the hip joint, and the
harnley low friction arthroplasty has been regarded as
gold standard. Multiple reports document the outcome
f the arthroplasty after up to 35 years, but patient pop-
lations, techniques and outcome measures vary widely.
enerally the outcome of the Charnley arthroplasty has been
uccessful for 10 years, but several studies have reported
ncreasing rates of revision beyond 10 years [1—5]. Neverthe-
ess, the Charnley stem continues to be highly regarded, and
s still the stem to which others are compared in the Norwe-
ian arthroplasty register [6]. Registry data provide valuable
nowledge, but has been criticized for relying merely on sur-
ival data, disregarding clinical and radiographic outcomes.
Some long-term studies report results utilize older
ementing techniques [7] or contain heterogeneous patient
opulations [1]. Also, outcomes data are reported in a vari-
ty of ways. A recent report on Charnley arthroplasties
ound an implant survival rate of 83% at 13 years but only a
6% clinical success rate [8].
We have investigated the outcome as well as survival
ata of 240 Charnley stems after 10 years implanted at a
ommunity hospital in Norway implanted with contempo-
ary cementing techniques and report our results in terms
f clinical success and radiographic ﬁndings at 10 years as
ell as implant survival after 11—14 years.
atients and methods
atients and surgical methods
etween April 1994 and June 1997, 215 patients treated at
ne clinic consented to take part in the study. Twenty-ﬁve
atients consented for both of their hips, resulting in a total
f 240 hips enrolled.
Patients were grouped according to the Charnley classi-
cation (Table 1) [9]. All surgeries were performed by ﬁve
urgeons using a direct lateral approach [10] and third gener-
tion cementing techniques with vacuum mixing, retrograde
lling of the canal, and pressurization prior to insertion of
he femoral component [11]. Cement preloaded with gen-
amycin (PalacosTM) and a Charnley stem (DePuy, Leeds,
K) with 22.225-mm head diameter was used in all cases,
nd a variety of stem shapes were available (Table 2).
he acetabular component was a cemented Charnley Ultra
igh Molecular Weight Polyethylene (UHMWPE) cup (DePuy,
eeds, UK) in 120 cases and a uncemented porous coatedarthoplasties or signiﬁcant medical or
psychological impairment
a B1 + B2.K. Bjørgul et al.
is aseptic loosening. We do not know the reason for this high-rate of loosening. As we believe
that our technique is adequate and patient population average, we suspect that this rate of
loosening is a characteristic of the implant. Results from this prospective cohort study add toRoundback 45 24
Short neck 1
Flanged 45 24
Extra heavy ﬂanged 45 9
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Table 3 Harris Hip Score, scales and subscales indicating the points possible for each subscale.
Pain 44
Function 46
Gait (33)
Limp (11)
Support (11)
Distance (11)
ADL (13)
Stairs (4)
Socks (4)
Sitting (4)
Transportation (1)
Range of motion 6
Absence of 4
100
Survival data were analyzed using Kaplan-Meier plots and
Cox regression analysis was used looking for possible predic-
tors of failure. P-values lower than 0.05 and non-overlapping
95% conﬁdence intervals were regarded as denoting statis-
tically signiﬁcant differences.
Results
Fifty-eight men and 157women were enrolled in the study.
Demographic information is shown in Tables 3 and 4. For
the 10-year follow-up, we were able to assess 158 cases
that had both radiographs and HHS. Twenty-six patients
were deceased and 25 patients could not attend a clini-
cal and radiographic examination due to advanced age and
concomitant illnesses. None of these patients had been
revised.
Harris Hip Score
HHS improved from a mean baseline value of 48.4 to 87.9 at
the 6-month control (Table 5). There was also a signiﬁcant
improvement from 6months to 2 years, and a drop from 5
to 10 years. After 10 years, HHS by 10-point brackets indi-
cates that 20 of 158 cases scored lower than 70 points (13%).
The lower values of total HHS is composed of a concomitant
deterioration of function and increase in pain (Table 6).
Radiographic results
There were one or more signs of loosening in 41 of the 158
cases (26%) available for 10-year follow-up. There was no
Table 4 Age and Body Mass Index (BMI) at surgery.
Mean 95% Conﬁdence interval for meandeformity
Total points
postoperatively and thereafter daily for the length of
the stay, which mean was 8.5 days (2—13 days). Cefuroxim
(Zinacef®) was given routinely in the study period for 1 day.
Postoperatively we allowed patients restricted weight bear-
ing on the day after surgery and all were encouraged to use
two crutches for at least 6weeks.
In this prospective randomized trial, not all variables of
interest were recorded prospectively. For that reason, we
undertook a chart review looking for the following parame-
ters: length of stay, details on the use of antibiotics both as a
primary prophylaxis and as secondary treatment for postop-
erative infections, detailed dosage of thromboprophylactic
agents. Appearance of an antibiotic in the charts was inter-
preted as an infection. We were not able to ﬁnd details on
urinary analysis or other hard evidence regarding the eti-
ology of an infection. However, the type of infection was
inferred from the type of antibiotic employed.
Methods of assessment
Patients were seen by a physiotherapist at 6months, 2 years,
5 years, and 10 years after surgery who obtained a Har-
ris Hip Score (HHS) [12] at each visit (Table 3). For this
study we computed mean scores with 95% conﬁdence inter-
vals. For the ﬁnal follow-up we also computed pain scores
and functional scores in brackets by 10. Radiographs were
obtained at all visits and analyzed by a radiologist not
directly involved in the study. Radiographic changes were
described according to the femoral zones of Gruen et al.
[13]. Changes have been included in the present analysis if
recorded as larger than 2mm, irrespective of length within
the zone. In addition to the clinical scores (HHS), radio-
graphic analysis and revision rates at 10 years, we calculated
implant survival rates. This was done by performing a sur-
vival analysis in August 2008 (11—14 years postoperatively),
using August 31st as a sensoring date.Statistical methods
Two-sample T-tests were used for comparing continuous
data, Chi2 tests were used to compare proportional data.
Lower bound Upper bound
Age 65.5 64.6 66.5
BMI 26.8 26.2 27.3
100 K. Bjørgul et al.
Table 5 Harris Hip Score at baseline and each follow-up including 95% conﬁdence intervals, minimum and maximum values.
N Mean 95% Conﬁdence interval for mean Minimum Maximum
Lower bound Upper bound
Baseline 240 48.4 46.6 50.2 6 94
Six months 237 87.9 86.6 89.3 41 100
Two years 225 91.3 89.9 92.7 45 100
Five years 191 91.0 89.4 92.7 38 100
Ten years 158 87.6 85.3 89.8 21 100
Table 6 Harris Hip Score (HHS) in brackets by 10 and corresponding pain and function score including 95% conﬁdence intervals.
Pain score Function score
HHS N Mean 95% Conﬁdence interval for mean Mean 95% Conﬁdence interval for mean
Lower bound Upper bound Lower bound Upper bound
90—100 91 43.7 43.5 43.9 44.1 43.5 44.6
80—89 38 42.0 40.7 43.3 33.6 32.2 35.0
70—79 9 40.0 34.8 45.2 27.3 22.7 31.9
60—69 11 36.9 31.5 42.4 20.0 13.6 26.4
<60 9 22.0 9.8 34.2 16.3 1.1 31.5
Total 158 41.4 40.3 42.5 37.8 36.2 39.3
association between radiographic signs of loosening and
HHS (Table 7), as ﬁve of the 20 patients with HHS below
70 had one or more signs of loosening and 36 of 138 with
HHS above 70 had signs of loosening. Conversely, of the 117
patients with no signs of loosening, 15 patients had a HHS
below 70 (13%).
Revisions
At the time of the last follow-up, 31 hips had been revised
(Table 8), 17 in the Charnley group and 14 in the Duraloc
group (P = 0.42; Chi2). Aseptic loosening was the most com-
mon reason for revision and this occurred in 21 cases
followed by infection (ﬁve), instability (four) and one case
of periprosthetic fracture.
The ﬁve infected hips were treated with two-stage revi-
sion after 5, 11, 14, 24 and 48months, all ﬁve occurred in the
Charnley group. There was a signiﬁcant association between
secondary use of antibiotics and later infection (P = 0.001;
Table 7 Number of patients with radiological signs of loos-
ening by Harris Hip Score (HHS).
HHS at 10 years Number of radiological
signs of loosening
Total
0 1 2 3
90—100 70 7 11 3 91
80—89 26 5 5 2 38
70—79 6 0 2 1 9
60—69 9 0 1 1 11
<60 6 1 1 1 9
Total 117 13 20 8 158
Chi2). Only one of the 188 patients who did not have a post-
operative urinary tract infection developed a hip infection,
whereas four of the 41 patients with postoperative uri-
nary tract infection later became infected. Relative risk for
prosthetic infection is 18.3 when a postoperative infection
occurred. The patients that became infected were signiﬁ-
cantly older (71.2 vs. 65.4 years; P = 0.035; T-test) than the
patients that did not become infected.
With aseptic loosening as end-point, implant survival was
88.9% whereas survival with all causes for revision as end-
point was 83.6%. The estimated mean survival of femur
according to the Kaplan-Meier analysis was 12.7 years (95%
conﬁdence interval: 12.2—13.3). In the Cox regression analy-
sis we did not ﬁnd any variables that predicted stem survival.
Dislocation and other complications
Seventeen patients reported instability, ﬁve out of 120 in
the Charnley group (3.3%) and 12 out of 120 (10.0%) in the
Duraloc group (P = 0.098; Chi2). There were 33 complications
that were not treated surgically, 15 in the Charnley group
and 18 in the Duraloc group (P = 0.32; Chi2).
Table 8 Reasons for revision and mean time (range) to
revision.
Number of
cases
Years to revision
(range)
Aseptic loosening 21 5.7 (1—13)
Infection 5 1.7 (0—4)
Instability 4 2.8 (1—5)
Fracture 1 0.9
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In the retrospective chart review, 52 cases (24 in the
Charnley group and 28 in the Duraloc group) were identi-
ﬁed in which a second course of antibiotics was given, of
which 41 cases were given antibiotics indicating a urinary
tract infection and 11 cases other antibiotics, indicating a
range of infection types.
Discussion
Determining the long-term outcome after THA requires
large studies, which are demanding and expensive. For
that reason, many studies now originate from arthoplasty
registries. Arthroplasty registries are powerful tools that
provide insights in the performance of implants in speciﬁc
regions. Originally designed to identify inferior products,
most provide revision rates or survival rates as the only
outcome measure. Survival data does not provide any infor-
mation on the clinical status of the patient and every
implant that is unrevised is considered a success. For that
reason it is important to supplement reports from arthro-
plasties with reports which also provide a clinical and
radiological outcomes. Moreover, registries depend on reli-
able reports on revision surgery. Revision surgery is often
performed at a different hospital many years later, and
failure to report the revision may falsely improve survival
data. Also, it is well-known that the composition of the
patient populations may vary with regards to gender, age
and Body Mass Index (BMI) and preoperative functional
level is important in predicting outcomes. Hence, clinical
studies are a crucial supplement to arthroplasty registry
studies.
Survival of the Charnley arthroplasty was reported to be
between 90 and 95% in registries [14,15], and survival in
clinical studies has been 85 to 96% [8,16—20] at mid-term
(10—15 years). In our study, we found a survival of 84%, which
was calculated as the number of surviving implants using the
number of implants available at 10 years as the denomina-
tor. Using the original number of 240 cases the survival is
240—31/240 = 87%. We do not know the reason for our results
in the lower range, but we believe that our technique and
patient population is representative in terms of age, gender,
BMI and activity level.
In our series, we used conventional cementing techniques
aiming for a 2—3mm cement mantle. However, the opti-
mal cementing technique has not been determined. Good
results have been obtained using an extremely thin cement
mantle, as well (the French paradox) [21]. Utilizing the
Charnley-Kerboull stem with only 25 reoperations in a series
of 222 patients under the age of 50 years [22], and in another
study the authors found a 15-year survival rate of 88.5% in
patients treated for osteonecrosis [23]. In a comparative
study the authors found that the polished or satin ﬁnish was
better than the matte surface [24].
HHS below 70 has been designated as a bad clinical out-
come. Forty-four points of the HHS is assigned to pain and
the rest is derived from some sort of physical activity. It is
well-known that physical activity and patient function dete-
riorate with time, and HHS is therefore heavily inﬂuenced
by patient function. For that reason a low HHS may signify
a low-level of activity more that unsuccessful arthroplasty
beyond 5—7 years. However, in this study it is clear that
i
f
i
i
[11—14 years 101
he pain and activity scores deteriorate in a parallel fash-
on, which supports using HHS as a parameter for evaluate
ong-term outcome.
We found radiological signs compatible with loosening in
3 cases (32%). The mode of failure of the Charnley stem has
een described [13] and is usually characterized by a radi-
lucent line in zone 1 followed by cement fracture around
he tip of the stem and increasing radiolucencies in zones 3
o 5. Subsidence and displacement into a varus position
nsues and there may be secondary cortical hypertrophy
n zone 3. However, the speed with which this process pro-
resses is variable and dependent on the total impact on the
rosthesis. The total impact is determined by the weight of
he patient and activity level. As the activity level of the
atients declines with aging, a prosthesis with radiographic
igns of loosening may remain stable and free of pain and
ot progress to revision. The patient should, however, be
ollowed closely.
The relationship between radiographic ﬁndings and clini-
al outcome is complicated. In the study by Hulleberg et al.
8] 13 of 118 hips had a HHS <70, but among those only six
ere radiographically loose. Conversely, six of the hips with
igns of loosening had a HHS >70, which was deﬁned as clin-
cally successful. In our study, 20 out of 158 hips scored <70
ut only ﬁve of those had one or more signs of loosening, and
one were deemed deﬁnitely loose. Beckenbaugh and Ilstrup
ound that only 8% of loose stems had required revision [25],
nd Ritter et al. found that 10 of 15 loose stems had been
evised [20]. Hartoﬁlakidis et al. revised 11 of 84 hips (13%)
ue to loosening of femur and acetabulum and another 11 of
2 (21%) femoral components displayed signs of loosening,
ut were unrevised [26]. The clinical outcome of patients
ith signs of loosening is often not described. In our study,
e did not ﬁnd any signiﬁcant association between radio-
ogical signs of loosening and clinical outcome, but other
uthors have noted this association previously [25].
There are limitations to any long-term study of this
ature. Because of death and deterioration in general
ealth, only 158 patients were available for clinical and
adiographic evaluation at the 10-year mark. While it is
as been shown that the results in patients lost to follow-
p are not as good as patients who stay in clinical studies
27], we were able to determine reason for loss to follow-
p for almost all of our patients. The vast majority of those
ho declined a follow-up visit doing so because of advanced
omorbid diseases, and not because of poor function of the
ip. In addition, our overall follow-up rate was similar to
ther long-term studies of hip function, even though our
atient population was signiﬁcantly older [28—30].
The lack of precise recording of comorbidities is also
limiting factor. Indices of comorbidities have previously
een shown to predict functional outcome as well as
omplications after THA [31—37]. Although the Charnley
lassiﬁcation is recommended for identifying functional
lasses [38], it is not a validated comorbidity instrument,
nd might not be sensitive enough to record subtle nuances
n patient health status. Recording level of activity is also
mportant [39,40] as it is of primary interest to the patients
or performing recreational activities [41] as well as for
mproving physical ﬁtness, although increased level of activ-
ty correlates with wear and potential failure of an implant
42—44]. The HHS contains assessment of physical function,
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ut it does not quantify what the patient actually does, only
hat he or she is capable of doing. Dedicated scales have
een developed for the sole purpose of estimating level of
ctivity before and after THA, but these scales were not
vailable for use in this study [44—47].
The issue of bilateral procedures is controversial since
he presence of two procedures in one patient violates the
ssumption of independent observations that many statis-
ical tests rely on [48—50]. However, other authors have
iscussed this and found that inclusion of bilateral proce-
ures may not alter the results under certain circumstances
8,50]. According to our study protocol, the presence of an
rthroplasty in the contralateral hip was not an exclusion
riterion. Nor was there any criteria excluding patients with
ad function of the contralateral hip that could be presumed
o necessitate another hip replacement during the study
eriod. It would also be vary hard to ﬁnd patients with uni-
ateral disease in sufﬁcient numbers to do a long-term study
s the other hip is known to need a replacement in at least
5% of the cases [50]. Hence, in our opinion, it was justiﬁed
o include the patients who had two arthoplasties during the
tudy and treat them as independent cases.
onclusion
his study provides evidence in support of the poor outcome
f the Charnley low friction arthroplasty after 10—14 years,
ocumenting a revision rate of 13%, poor clinical outcome
nd radiographic signs of loosening in 26% of the cases.
e do not recommend this implant for patients with a life
xpectancy in excess of 10 years, possible reserving the stem
or hemiarthroplasties after hip fracture in the elderly pop-
lation.
onﬂict of interest statement
one.
eferences
[1] Wroblewski BM, Siney PD, Fleming PA. Charnley low-frictional
torque arthroplasty in patients under the age of 51 years.
Follow-up to 33 years. J Bone Joint Surg Br 2002;84:540—3.
[2] Hartoﬁlakidis G. Survival of the Charnley low-friction arthro-
plasty. A 12—24-year follow-up of 276 cases. Acta Orthop Scand
1997;Suppl 275:27—9.
[3] Hozack WJ, Rothman RH. Long-term survival of the Charn-
ley low-friction total hip arthroplasty. Semin Arthroplasty
1990;1:3—6.
[4] Callaghan JJ, Templeton JE, Liu SS, et al. Results of Charn-
ley total hip arthroplasty at a minimum of thirty years. A
concise follow-up of a previous report. J Bone Joint Surg Am
2004;86:690—5.
[5] Callaghan JJ, Liu SS, Firestone DE, et al. Total hip arthroplasty
with cement and use of a collared matte-ﬁnish femoral com-
ponent: nineteen to twenty-year follow-up. J Bone Joint Surg
Am 2008;90:299—306.[6] Furnes O, Havelin LI, Espehaug B, Steindal K, Sørås TE. Rapport
2008. Nasjonalt Kompetansesenter for Leddproteser; 2008,
p. 50—50.
[7] Berry DJ, Harmsen WS, Cabanela ME, Morrey BF. Twenty-
ﬁve-year survivorship of two thousand consecutive primary
[K. Bjørgul et al.
Charnley total hip replacements: factors affecting survivorship
of acetabular and femoral components. J Bone Joint Surg Am
2002;84:171—7.
[8] Hulleberg G, Aamodt A, Espehaug B, Benum P. A clinical
and radiographic 13-year follow-up study of 138Charnley
hip arthroplasties in patients 50—70 years old: comparison
of university hospital data and registry data. Acta Orthop
2008;79:609—17.
[9] Charnley J, Halley DK. Rate of wear in total hip replacement.
Clin Orthop 1975;112:170—9.
10] Hardinge K. The direct lateral approach to the hip. J Bone Joint
Surg Br 1982;64:17—9.
11] Rasquinha VJ, Dua V, Rodriguez JA, Ranawat CS. Fifteen-
year survivorship of a collarless, cemented, normalized
femoral stem in primary hybrid total hip arthroplasty with a
modiﬁed third-generation cement technique. J Arthroplasty
2003;18:86—94.
12] Harris WH. Traumatic arthritis of the hip after dislocation and
acetabular fractures: treatment by mold arthroplasty. An end-
result study using a new method of result evaluation. J Bone
Joint Surg Am 1969;51:737—55.
13] Gruen TA, McNeice GMP, Amstutz HC. ‘‘Modes of failure’’ of
cemented stem-type femoral components: A radiographic anal-
ysis of loosening. Clin Orthop 1979;141:17—27.
14] Havelin LI, Engesaeter LB, Espehaug B, Furnes O, Lie SA,
Vollset SE. The Norwegian Arthroplasty Register: 11 years and
73,000 arthroplasties. Acta Orthop Scand 2000;71:337—53.
15] Allami MK, Fender D, Khaw FM, Sandher DR, Esler C, Harper
WM, et al. Outcome of Charnley total hip replacement across
a single health region in England. The results at ten years
from a regional arthroplasty register. J Bone Joint Surg Br
2006;88:1293—8.
16] Garellick G, Herberts P, Stromberg C, Malchau H. Long-term
results of Charnley arthroplasty. A 12—16-year follow-up study.
J Arthroplasty 1994;9:333—40.
17] Kobayashi S, Takaoka K, Saito N, Hisa K. Factors affecting
aseptic failure of ﬁxation after primary Charnley total hip
arthroplasty. Multivariate survival analysis. J Bone Joint Surg
Am 1997;79:1618—27.
18] Skeie S, Lende S, Sjoberg EJ, Vollset SE. Survival of the Charnley
hip in coxarthrosis. A 10—15-year follow-up of 629 cases. Acta
Orthop Scand 1991;62:98—101.
19] Sochart DH, Hardinge K. Comparison of the Wrightington
FC hip with the Charnley low-friction arthroplasty 10- to
15-year results and survival analysis. J Bone Joint Surg Br
1998;80:577—84.
20] Ritter MA, Zhou H, Keating CM, Keating EM, Faris PM, Meding JB,
et al. Radiological factors inﬂuencing femoral and acetabular
failure in cemented Charnley total hip arthroplasties. J Bone
Joint Surg Br 1999;81:982—6.
21] Langlais F, Kerboull M, Sedel L, Ling RS. The ‘‘French paradox’’.
J Bone Joint Surg Br 2003;85:17—20.
22] Kerboull L, Hamadouche M, Courpied JP, Kerboull M. Long-
term results of Charnley-Kerboull hip arthroplasty in patients
younger than 50 years. Clin Orthop 2004;418:112—8.
23] Nich C, Courpied JP, Kerboull M, Postel M, Hamadouche M.
Charnley-Kerboull total hip arthroplasty for osteonecrosis of
the femoral head a minimal 10-year follow-up study. J Arthro-
plasty 2006;21:533—40.
24] Hamadouche M, Baque F, Lefevre N, Kerboull M. Minimum 10-
year survival of Kerboull cemented stems according to surface
ﬁnish. Clin Orthop 2008;466:33239.
25] Beckenbaugh RD, Ilstrup DM. Total hip arthroplasty. J Bone
Joint Surg Am 1978;60:306—13.
26] Hartoﬁlakidis G, Karachalios T, Zacharakis N. Charnley low fric-
tion arthroplasty in young patients with osteoarthritis. A 12- to
24-year clinical and radiographic followup study of 84 cases.
Clin Orthop 1997;341:51—4.
fter
[
[
[
[
[
[
[
[
[
[
[The Charnley stem: Clinical, radiological and survival data a
[27] Murray DW, Britton AR, Bulstrode CJ. Loss to follow-up matters.
J Bone Joint Surg Br 1997;79:254—7.
[28] Grobler GP, Learmonth ID, Bernstein BP, Dower BJ. Ten-year
results of a press-ﬁt, porous-coated acetabular component. J
Bone Joint Surg Br 2005;87:786—9.
[29] Petersen MB, Poulsen IH, Thomsen J, Solgaard S. The hemi-
spherical Harris-Galante acetabular cup, inserted without
cement. The results of an eight to eleven-year follow-up
of one hundred and sixty-eight hips. J Bone Joint Surg Am
1999;81:219—24.
[30] Clohisy JC, Harris WH. The Harris-Galante porous-coated
acetabular component with screw ﬁxation. An average ten-
year follow-up study. J Bone Joint Surg Am 1999;81:66—
73.
[31] Imamura K, Black N. Does comorbidity affect the outcome of
surgery? Total hip replacement in the UK and Japan. Int J Qual
Health Care 1998;10:113—23.
[32] Greenﬁeld S, Apolone G, McNeil BJ, Cleary PD. The impor-
tance of co-existent disease in the occurrence of postoperative
complications and one-year recovery in patients undergoing
total hip replacement. Comorbidity and outcomes after hip
replacement. Med Care 1993;31:141—54.
[33] Greenﬁeld S. The state of outcome research: Are we on target?
N Engl J Med 1987;320:1142—3.
[34] Keener JD, Callaghan JJ, Goetz DD, Pederson D, Sullivan P,
Johnston RC. Long-term function after Charnley total hip
arthroplasty. Clin Orthop 2003;417:148—56.
[35] Fortin PR, Clarke AE, Joseph L, et al. Outcomes of total hip
and knee replacement: preoperative functional status pre-
dicts outcomes at six months after surgery. Arthritis Rheum
1999;42:1722—8.
[36] Groll DL, To T, Bombardier C, Wright JG. The development of
a comorbidity index with physical function as the outcome. J
Clin Epidemiol 2005;58:595—602.
[37] Lubbeke A, Katz JN, Perneger TV, Hoffmeyer P. Primary and
revision hip arthroplasty: 5-year outcomes and inﬂuence of age
and comorbidity. J Rheumatol 2007;34:394—400.
[38] Callaghan JJ, Dysart SH, Savory CF, Hopkinson WJ. Assessing
the results of hip replacement. A comparison of ﬁve different
rating systems. J Bone Joint Surg Br 1990;72:1008—9.
[11—14 years 103
39] Beaule PE, Dorey FJ, Hoke R, Leduff M, Amstutz HC. The value
of patient activity level in the outcome of total hip arthro-
plasty. J Arthroplasty 2006;21:547—52.
40] Dorey FJ, Amstutz HC. The need to account for patient
activity when evaluating the results of total hip arthroplasty
with survivorship analysis. J Bone Joint Surg Am 2002;84:
709—10.
41] Wright JG, Rudicel S, Feinstein AR. Ask patients what they
want. Evaluation of individual complaints before total hip
replacement. J Bone Joint Surg Br 1994;76:229—34.
42] Flugsrud GB, Nordsletten L, Espehaug B, Havelin LI, Meyer HE.
The effect of middle-age body weight and physical activity on
the risk of early revision hip arthroplasty: a cohort study of
1,535 individuals. Acta Orthop 2007;78:99—107.
43] Lavernia CJ, Sierra RJ, Hungerford DS, Krackow K. Activity
level and wear in total knee arthroplasty: a study of autopsy
retrieved specimens. J Arthroplasty 2001;16:446—53.
44] Saleh KJ, Mulhall KJ, Bershadsky B, et al. Development and
validation of a lower-extremity activity scale. Use for patients
treated with revision total knee arthroplasty. J Bone Joint Surg
Am 2005;87:1985—94.
45] Naal FD, Impellizzeri FM, Leunig M. Which is the best activity
rating scale for patients undergoing total joint arthroplasty?
Clin Orthop 2009;467:958—65.
46] Silva M, McClung CD, la Rosa MA, Dorey FJ, Schmalzried TP.
Activity sampling in the assessment of patients with total joint
arthroplasty. J Arthroplasty 2005;20:487—91.
47] Zahiri CA, Schmalzried TP, Szuszczewicz ES, Amstutz HC.
Assessing activity in joint replacement patients. J Arthroplasty
1998;13:890—5.
48] Ranstam J. Problems in orthopedic research: dependent obser-
vations. Acta Orthop Scand 2002;73:447—50.
49] Bryant D, Havey TC, Roberts R, Guyatt G. How many
patients? How many limbs? Analysis of patients or limbs in the
orthopaedic literature: a systematic review. J Bone Joint Surg
Am 2006;88:41—5.
50] Lie SA, Engesaeter LB, Havelin LI, Gjessing HK, Vollset
SE. Dependency issues in survival analyses of 55,782 pri-
mary hip replacements from 47,355 patients. Stat Med
2004;23:3227—40.
